Progyny, Inc. Announces Fourth Quarter 2024 ResultsReports Quarterly Revenue of $298.4 Million, Reflecting 10.6% GrowthGenerated $52.2 Million of Quarterly Operating Cash FlowIssues Financial Guidance for 2025, Reflecting Tenth Consecutive Year of Revenue Growth
Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2024 Results ReportNEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, will report its financial results for the quarterly period and full year ended December 31, 2024, after the close of the market on Thursday, February 27, 2025.
Progyny, Inc. Enhances Suite of Services with Acquisition of BenefitBumpProvides expecting parents with a concierge-level service model that delivers expert guidance, navigation and support for parental leave planning
Progyny Appoints Healthcare Veteran Debra Morris to Board of DirectorsNEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building and women’s health benefits solution, today announced the appointment of 30-year healthcare industry veteran Debra Morris to its board of directors, effective January 16, 2025.
Securities Fraud Investigation Into Progyny, Inc. (PGNY) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Progyny, Inc. (“Progyny” or the “Company”) (
NASDAQPGNY) investors concerning the Company’s possible violations of the federal securities laws.
Progyny, Inc. (PGNY) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Law Offices of Howard G. Smith announces an investigation on behalf of Progyny, Inc. (“Progyny” or the “Company”) (
NASDAQPGNY) investors concerning the Company’s possible violations of federal securities laws.
Progyny to Discuss Updated Financial Expectations at Upcoming JP Morgan Healthcare ConferenceAnticipates Fourth Quarter and Full Year Results to be Slightly Above Previously Provided Financial Guidance
Robbins LLP Informs Progyny, Inc. Stockholders that it is Investigating the Officers and Directors of PGNY to Determine if They Breached Fiduciary Duties Owed to ShareholdersSAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Progyny, Inc. (
NASDAQPGNY) to determine whether certain Progyny officers and directors violated securities laws and breached fiduciary duties to shareholders. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States.
Progyny, Inc. Announces Third Quarter 2024 ResultsSales Season Yields Over 80 New Clients, 1.1 Million New Covered LivesSelected by a Leading National Health Plan and a Regional Health Plan as Their Preferred Partner1.5 Million Lives Adopt Newest Services in Maternity and/or Menopause Programs in 2025
Progyny, Inc. Announces Details for Its Third Quarter 2024 Results ReportNEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, will report its financial results for the quarterly period ended September 30, 2024 after the close of the market on Tuesday, November 12, 2024.
PGNY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Progyny, Inc. and Encourages Investors to Contact the Firm!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. (“Progyny” or “the Company”) (
NASDAQPGNY). Investors who purchased Progyny securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/PGNY.
PGNY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Progyny, Inc. and Encourages Investors to Contact the Firm!
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. (“Progyny” or “the Company”) (
NASDAQPGNY). Investors who purchased Progyny securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/PGNY.
The Law Offices of Frank R. Cruz Announces Investigation of Progyny, Inc. (PGNY) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Progyny, Inc. (“Progyny” or the “Company”) (
NASDAQPGNY) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Progyny, Inc. Announces Second Quarter 2024 ResultsAchieves Record Quarterly Adjusted EBITDA, Strong Cash Flow Conversion RateBoard Authorizes Repurchase of $100 Million of Common Stock
The Broken Brown Egg and Progyny Announce the 2024 Awareness, Hope, and Activism Grant™ to Support BIPOC Individuals and Couples in Family BuildingNEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, and The Broken Brown Egg, a nonprofit supporting BIPOC individuals and couples experiencing infertility, today launched the 2024 Awareness, Hope, and Activism (AHA) Grant™.
Progyny, Inc. Announces Details for Its Second Quarter 2024 Results ReportNEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, will report its financial results for the quarterly period ended June 30, 2024 after the close of the market on Tuesday, August 6, 2024.
Progyny, Inc. Announces Enhanced Global Services with Acquisition of AprylNEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, today announced an expansion of its global offering with the acquisition of Apryl, a Berlin-based fertility benefits platform founded in 2019. This acquisition enhances Progyny’s guided, concierge support that enables employees around the world to navigate the complexities of fertility and family building care.
New Survey from Progyny Shows Strong LGBTQ+ Demand for Inclusive Family Building BenefitsNEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, today released findings from its 2024 LGBTQ+ family building survey. The report, which surveyed over 1,100 LGBTQ+ individuals in the U.S. planning to build their families, highlights the unique challenges LGBTQ+ patients face, including struggles with insufficient access to care, financial constraints, and lack of mental health support throughout their family building journey.
Progyny, Inc. Announces Additional Share Repurchase ProgramNEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, announced today that its Board of Directors has approved a share repurchase program to repurchase up to $100 million of its common stock. This follows the program that was previously announced on February 29, 2024. The program will be funded through available cash balances.
Progyny, Inc. Announces First Quarter 2024 ResultsEarly Sales Activity and New Partnerships Provide Strong Start to Selling Season, Affirming Continued Demand for Fertility and Family Building Solutions
Progyny, Inc. Announces Details for Its First Quarter 2024 Results ReportNEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, will report its financial results for the quarterly period ended March 31, 2024 after the close of the market on Thursday, May 9, 2024.
Progyny and RESOLVE to Honor National Infertility Awareness Week® with Events Spanning Coast to CoastThe leading benefits solution and largest infertility advocacy non-profit will host a series of events aimed at raising awareness for the millions of individuals facing family building challenges
Progyny, Inc. Announces Share Repurchase ProgramNEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, announced today that its Board of Directors has approved a share repurchase program to repurchase up to $100 million of its common stock. The program will be funded through available cash balances.
Progyny, Inc. Announces Fourth Quarter 2023 ResultsReports Record Full Year Revenue of $1,088.6 Million, Reflecting 38% GrowthAchieves 49% Growth in Adjusted EBITDA to Record $187.1 MillionIssues Financial Guidance for 2024, Crossing the $1.3 Billion Milestone at Midpoint
Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2023 Results ReportNEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, will report its financial results for the quarterly period and full year ended December 31, 2023 after the close of the market on Tuesday, February 27, 2024.
